Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Cited by (1,000)

Items 701–800 of 1,000

1. Coronavirus Vaccines
   Stanley M. Perlman, Mark R. Denison · 2023 · Elsevier eBooks
2. Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges
   Rohan Kapur, Kenji Okumura, Suguru Ohira, Ameesh M. Isath, Aditya Gandhi, Marina Keller, Rajat Nog, Alan L. Gass, David Spielvogel, Steven L Lansman et al. · 2024 · Cardiology in Review
3. Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2
   Hengrui Hu, Chao Leng, Yanni Shu, Peng Lü, Fan Wu, Jia Liu, Xiaolu Zhang, Wei Zhou, Qinghong Xiao, Yufeng Li et al. · 2025 · Journal of Virology
4. Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial
   Ahmad Mourad, Gregory A. Grandits, Lianne K. Siegel, Nicole Wyman Engen, Christina E. Barkauskas, Nnakelu Eriobu, Mamta K. Jain, Tomas Østergaard Jensen, Adit A. Ginde, Elizabeth S. Higgs et al. · 2025 · Clinical Microbiology and Infection
5. Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics
   Giulia Dowgier, Agnieszka Hobbs, David Greenwood, Marianne Shawe‐Taylor, Phoebe Stevenson-Leggett, James Bazire, Rebecca Penn, Ruth Harvey, Vincenzo Libri, George Kassiotis et al. · 2025 · Vaccine
6. Therapeutic applications of interface-mimicking peptides for targeting the SARS-CoV-2 NSP12-NSP8 RdRp complex
   Mark Anthony B. Casel, Jae‐Woo Ahn, Hyunjoon Kim, Isaac Choi, Seung‐Gyu Jang, Rare Rollon, Hua‐Long Ji, Mina Yu, Seong Cheol Min, Min‐Suk Song et al. · 2025 · Molecular Therapy
7. Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease – history, present, and future. Literature review
   Petar Yordanov Atanasov, Maria Georgieva Moneva-Sakelarieva, Yozlem Ali Kobakova, Stefka Achkova Ivanova, Maria Stamova Vakrilova Becheva, Angelina Georgieva Kirkova-Bogdanova, Maria Sevdelinova Chaneva, Ventseslava Petrova Atanasova, Radoslav Fedeev Todorov, Nikolay Zarkov Bashev et al. · 2025 · Pharmacia
8. Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV ‐2 Variants
   Qianwen Wang, Ahmed Nader, Amanda Peppercorn, Andrew Skingsley, Emily J. Lloyd, Alberto Ospina Stella, Jill Walker, Chad Garner · 2025 · Clinical and Translational Science
9. Comparative analysis of clinically approved lipid nanoparticles for intranasal siRNA delivery against SARS-CoV-2
   Yuan Zhang, Matt D. Johansen, Scott Ledger, Rebecca Shipley, Guanshu Zhao, Ernest Moles, Stuart Grant Turville, Pall Thordarson, Philip M. Hansbro, Maria Kavallaris et al. · 2026 · Drug Delivery and Translational Research
10. Budesonide bests COVID-19
    Samantha S Moe, Gary Michael Allan, Anthony D. Train · 2022 · Canadian Family Physician
11. Association of SARS-CoV-2 RNA Copy Number with the COVID-19 Mortality Rate and Its Effect on the Predictive Performance of Mortality in Severe Cases
    Takahiro Mitsumura, Tsukasa Okamoto, Mizuho Tosaka, Takashi Yamana, Sho Shimada, Yuki Iijima, Rie Sakakibara, Sho Shibata, Takayuki Honda, Tsuyoshi Shirai et al. · 2022 · Japanese Journal of Infectious Diseases
12. Management of Severe and Critical COVID-19 Infection with Immunotherapies
    Janhavi Athale, Jolie Gallagher, Lindsay M. Busch · 2022 · Infectious Disease Clinics of North America
13. Effectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease
    L. Zhao, Lin Fu, Yu-Qin He, Han Li, Yi-Xuan Song, Shao-Yan Liu · 2023 · Vaccines
14. Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction
    Kei Yamamoto, Yusuke Ohsiro, Tetsuya Suzuki, Michiyo Suzuki, Sayaka Miura, Maki Nagashima, Noriko Iwamoto, Junko S. Takeuchi, Moto Kimura, Wataru Sugiura et al. · 2023 · PLoS ONE
15. TO MARKET, TO MARKET–2021: MACROMOLECULAR THERAPEUTICS
    Nicholas J. Agard, Peter S. Dragovich, Ryan L. Kelly, Shion An Lim, Allison M. Beal, Ian Moench, Si-Jie Chen, Anna M. Gram, Pei‐Pei Kung · 2022 · Medicinal chemistry reviews
16. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
    Daria S. Fomina, Лебедкина Марина Сергеевна, Anna A. Iliukhina, Ковыршина Анна Витальевна, Artem Y. Shelkov, Sergey S. Andreev, Anton A. Chernov, Inna V. Dolzhikova, Tatyana S. Kruglova, Gerelma V. Andrenova et al. · 2023 · Frontiers in Immunology
17. Real-world data to evaluate effects of a multi-level dissemination strategy on access, outcomes, and equity of monoclonal antibodies for COVID-19
    Mika K. Hamer, Chelsea Sobczak, Lindsey Whittington, Rachel L. Bowyer, Ramona Koren, Joel A. Begay, Hillary D. Lum, Adit A. Ginde, Matthew K. Wynia, Bethany M. Kwan · 2023 · Journal of Clinical and Translational Science
18. Application of a Receptor-Binding-Domain-Based Simple Immunoassay for Assessing Humoral Immunity against Emerging SARS-CoV-2 Virus Variants
    Orsolya Mózner, Judit Moldvay, Kata Sára Szabó, Dorottya Vaskó, Júlia Domján, Dorottya Ács, Zoltán Ligeti, Csaba Fehér, Edit Hirsch, László Géza Puskás et al. · 2023 · Biomedicines
19. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
    Anais Romero, Charlotte Laurent, Ludivine Lebourg, Véronique Lemee, Mélanie Hanoy, Frank Le Roy, Steven Grangé, Mathilde Lemoine, Dominique Guerrot, Dominique Bertrand · 2024 · Viruses
20. CLINICAL EFFECTIVENESS OF CASIRIVIMAB AND IMDEVIMAB COMPARED WITH STANDARD OF CARE IN COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Amirhossein Orandi, Mojgan Mohajeri Iravani, Mohsen Mansouri, Mina Salajegheh, Mehdi Jalili, Morad Esmaiil Zali, Hamid Babaei, Ebadallah Shiri Malekabad, Saeed Khorramnia · 2024 · Studies in Medical Sciences
21. Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V
    Yuan-Ling Xia, Wen-Wen Du, Yongping Li, Yan Tao, Zhi-Bi Zhang, Songming Liu, Yun‐Xin Fu, Ke‐Qin Zhang, Shu-Qun Liu · 2024 · Journal of Chemical Information and Modeling
22. Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials
    Ana Flávia Amorim, Joselin Valeska Martinez-Sobalvarro, Larissa Helena Torres, Tiago Marques dos Reis · 2024 · Naunyn-Schmiedeberg s Archives of Pharmacology
23. Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study
    Antonio Russo, Mariantonietta Pisaturo, Chiara Cacace, Augusta Troise, Gabriele Granata, Pierantonio Grimaldi, Enrico Allegorico, Francesca Ambrisi, Martina Papillo, Fabio Giuliano Numis et al. · 2025 · Pathogens
24. Antiviral therapy and immunotherapy of COVID-19
    Clara Crespillo‐Andújar, Santiago Moreno · 2021 · Revista Española de Quimioterapia
25. The effect of casirivimab with imdevimab on disease progression in nonsevere COVID‐19 patients in a single hospital in Japan
    Junpei Komagamine, Taku Yabuki, Satsuki Yoshihara, Nao Tanaka · 2021 · Journal of General and Family Medicine
26. New drug: Sotrovimab for COVID-19
    2021 · Australian Prescriber
27. Pharmacologic Treatment and Management of Coronavirus Disease 2019
    Amy Hirsch Shumaker, Adarsh Bhimraj · 2022 · Infectious Disease Clinics of North America
28. Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of COVID-19 Patients Treated With Intravenous Infusion or Subcutaneous Injection
    Emily B Rubin, Mofei Liu, Anita Giobbie‐Hurder, Lauren A Canha, C. Elizabeth Keleher, Keri M. Sullivan, Michael Lawrence Dougan · 2022 · Open Forum Infectious Diseases
29. Delivering Monoclonal Antibody Infusions to Novel Outpatient Settings
    Amy Minnich, Daniel Rocha, Yirui Hu, Keith Boell, Greg F. Burke · 2022 · NEJM Catalyst
30. Tolerance and clinical outcomes of COVID ‐19 antiviral therapy in long‐term care residents
    Shireesha Vuppalanchi, Lindsay Weaver, Kristina Box, Pam Pontones · 2022 · Journal of the American Geriatrics Society
31. Treatment paradigms in Parkinson's Disease and Covid-19
    Iro Boura, Lucia Batzu, Espen Dietrichs, К. Ray Chaudhuri · 2022 · International review of neurobiology
32. Monoclonal Antibodies to Treat COVID-19 in Rheumatoid Arthritis: A Case Report and a Clinical Appraisal of Selected Drug Trials
    Arvind Chopra · 2022 · Indian Journal of Rheumatology
33. Фармакологические вещества, проявляющие противовирусную активность в отношении коронавируса SARS-CoV-2
    Дилара Ахметовна Еникеева, Н. Г. Бондарчук · 2022 · Экспериментальная и клиническая фармакология
34. Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV ‐2
    Mohamed A. Kamal, Andreas Kuznik, Luyuan Qi, Witold Więcek, Mohamed A. Hussein, Hazem E. Hassan, Kashyap Patel, Thomas Obadia, Masood Khaksar Toroghi, Daniela J. Conrado et al. · 2022 · Clinical Pharmacology & Therapeutics
35. Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19
    Julij Šelb, Barbara Bitežnik, Urška Bidovec‐Stojkovič, Boštjan Rituper, Katarina Osolnik, Peter Kopač, Petra Svetina, Kristina Cerk Porenta, Franc Šifrer, Petra Lorber et al. · 2022 · ERJ Open Research
36. Outcomes of Monoclonal Antibody Infusion Treatment During Delta (B.1.617.2) and Omicron (B.1.1.529) COVID 19 Variant Surges among Vaccinated and Unvaccinated Patients
    Haider Ghazanfar, Asim Haider, Hitesh Gurjar, Nolberto Hernandez, Abhilasha Jyala, Tanushree Bhatt, Cosmina B. Zeana, Sridhar S. Chilimuri · 2022 · Health Services Insights
37. Neutralizing antibodies for SARS-CoV-2 infection
    Juan Berenguer · 2022 · Revista Española de Quimioterapia
38. S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Registernummer: 021-031 – Stand 15. Juni 2022
    Frank Tacke, Markus Cornberg, Martina R. Sterneck, Jonel Trebicka, Utz Settmacher, Wolf O. Bechstein, Thomas Berg, Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), vertreten durch Frank Tacke, Markus Cornberg, Martina Sterneck, Jonel Trebicka, Thomas Berg, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), vertreten durch Wolf Bechstein · 2022 · Zeitschrift für Gastroenterologie
39. Structural insights into the rational design of a nanobody that binds with high affinity to the SARS-CoV-2 spike variant
    Keishi Yamaguchi, Itsuki Anzai, Ryota Maeda, Maiko Moriguchi, Tokiko Watanabe, Akihiro Imura, Akifumi Takaori‐Kondo, Tsuyoshi Inoue A · 2022 · The Journal of Biochemistry
40. Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic
    Солдатов Александр Алексеевич, Горенков Дмитрий Витальевич, Вадим Анатольевич Меркулов, В. П. Бондарев · 2022 · Biological Products Prevention Diagnosis Treatment
41. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
    Martin Heller, Clara Henrici, Judith Büttner, Sebastian Leube, Isabelle Treske, Petra Pospischil, Michael Doll, Ilka Schanz, Agnes Hallier, Eva Maria Herrmann et al. · 2023 · International Journal of Infectious Diseases
42. Effect of the Timing of Amubarvimab/Romlusevimab (BRII-196/198) Administration on Progression to Severe Disease in Elderly Patients with COVID-19 Infection: A Retrospective Cohort Study
    Yonghao Xu, Ying Liu, Ruiqiang Zheng, Shujie Si, Xi Yin, Xilong Deng, Gang Wang, Liang Zhou, Manshu Li, Ya Wang et al. · 2023 · Intensive Care Research
43. COVID-19 (novel SARS-CoV-2) neurological illness
    David S. Younger · 2023 · Handbook of clinical neurology
44. Fully Human Herpesvirus-Specific Neutralizing IgG Antibodies Generated by EBV Immortalization of Splenocytes-Derived from Immunized Humanized Mice
    Sebastian Julian Theobald, Elena Fiestas, Andreas Schneider, Benjamin Ostermann, Simon Danisch, Constantin von Kaisenberg, Jan Rybniker, Wolfgang Hammerschmidt, Reinhard Zeidler, Renata Stripecke · 2023 · Cells
45. Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study
    Daisuke Minakata, Tomoyuki Uchida, Aya Nakano, Ken Takase, Nodoka Tsukada, Hiroshi Kosugi, Eri Kawata, Takahiko Nakane, Hiroyuki Takahashi, Tomoyuki Endo et al. · 2024 · International Journal of Hematology
46. Integration of individualized and population-level molecular epidemiology data to model COVID-19 outcomes
    Ted Ling-Hu, Lacy M. Simons, Taylor J. Dean, Estefany Rios-Guzman, Matthew Caputo, Arghavan Alisoltani, Chao Qi, Michael Malczynski, Timothy Blanke, Lawrence J. Jennings et al. · 2024 · Cell Reports Medicine
47. Association between monoclonal antibody therapy, vaccination, and longer‐term symptom resolution after acute COVID‐19
    Samantha C. Roberts, Sarah E. Jolley, Laurel E. Beaty, Neil R. Aggarwal, Tellen D. Bennett, Nichole E. Carlson, Lindsey E. Fish, Bethany M. Kwan, Seth Russell, Adane F. Wogu et al. · 2024 · Journal of Medical Virology
48. Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
    Qin Yalan, Hao Lingfang, Liu Xisong, Run Liang, Zhang Junjing, Zhang’ An · 2024 · BMC Pharmacology and Toxicology
49. Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients
    Jan Schmieszek, Thomas Fuehner, Isabelle Renger, Tobias Welte, Jan Menne, Jan Fuge, Maria P. van't Klooster, Andrea Paul, Alina Siegert, Dan‐Nicolae Borchina et al. · 2024 · Therapeutic Apheresis and Dialysis
50. The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
    Katie Bechman, Amelia C. A. Green, Mark Russell, Zijing Yang, Bang Zheng, Sam Norton, Rebecca Smith, Amir Mehrkar, Seb Bacon, Ben M. Goldacre et al. · 2024 · Journal of Infection
51. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
    Daniele Focosi · 2024 · Current topics in microbiology and immunology
52. Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab
    Alexander Killer, Smaranda Gliga, Pascal Massion, Carla Ackermann, Clara de Angelis, Charlotte Flasshove, Noemi F. Freise, Nadine Lübke, Jörg Timm, Kirsten Alexandra Eberhardt et al. · 2024 · Infection
53. Comparative Effectiveness of Outpatient COVID‐19 Therapies in Solid Organ Transplant Recipients
    Zachary A. Yetmar, Viengneesee Thao, David A. Helfinstine, Kelly M. Pennington, Raymund Rabe Razonable · 2025 · Transplant Infectious Disease
54. Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis
    Norah Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Nikolayevich Iezhitsa, Renu Agarwal · 2025 · British Journal of Clinical Pharmacology
55. A BSL-2 chimeric system designed to screen SARS-CoV-2 E protein ion channel inhibitors
    Vashi Negi, Richard J. Kuhn · 2025 · Journal of Virology
56. COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates
    Emily Ruth Levy, Joseph A. Dearani, Jennifer A. Blumenthal, Jonathan N. Johnson, David M. Overman, Elizabeth H. Stephens, Kathleen Chiotos · 2022 · World Journal for Pediatric and Congenital Heart Surgery
57. Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series
    Kenichiro Takeda, Hajime Kasai, Seiichiro Sakao, Mikihito Saito, Kohei Shikano, Akira Naito, Mitsuhiro Abe, Takeshi Kawasaki, Misuzu Yahaba, Toshibumi Taniguchi et al. · 2022 · American Journal of Case Reports
58. Haematological and biochemical pathology markers for a predictive model for ITU admission and death from COVID‐19: A retrospective study
    Anuja Rasarathnam, Terrence Haynes‐Smith, Wassif S. Wassif, Michael S. Dodd · 2022 · eJHaem
59. Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation
    Gianpaolo Marcacci, Nicola Coppola, Emanuela Madonna, Cristina Becchimanzi, Stefania De Pascalis, Silvia D’Ovidio, Stefania Crisci, Piera Maiolino, Rosaria De Filippi, Antonio Pinto · 2022 · Infectious Agents and Cancer
60. What progress has been made in treatment of immunocompromised COVID-19 patients?
    Florence Ader, J. Bauer · 2022 · Infectious Diseases Now
61. Pregnancy outcomes after administration of monoclonal antibody therapy for COVID-19
    Maria T. Martinez-Baladejo, Ashley Graul, Tyler Gifford, Dennis M McGorry, Joseph Bell, Hannah B. Anastasio, Israel Zighelboim, Jorge E. Tolosa · 2022 · American Journal of Obstetrics & Gynecology MFM
62. Monoclonal antibodies for the treatment of COVID-19 infection in children
    Kelly M Ling, Michael Lawrence Dougan · 2022 · Expert Review of Anti-infective Therapy
63. The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
    Arielle R. Nagler, Leora Idit Horwitz, Simon Jones, Christopher Michael Petrilli, Eduardo Iturrate, Jennifer Lighter, Michael Phillips, Brian P. Bosworth, Bruce Polsky, Frank Volpicelli et al. · 2022 · American Journal of Health-System Pharmacy
64. Single Center Experience Using Monoclonal COVID-19 Antibodies in the Management of Immunocompromised Patients with COVID-19
    David Klank, Bernd Claus, Raoul Bergner, Peter Paschka · 2022 · Microorganisms
65. The Concomitant Use o f Melatonin and Bebtelovimab as a Treatment Strategy for Omicron and Future Variants of Concern
    Emine Erdağ · 2022 · International Journal Of Pharmaceutical Research And Allied Sciences
66. Drug Cocktail Formulation via Circuit Design
    Douglas Raymond Beahm, Yijie Deng, Thomas M. DeAngelo, Rahul Sarpeshkar · 2023 · IEEE Transactions on Molecular Biological and Multi-Scale Communications
67. Drug effectiveness for COVID-19 inpatients inferred from Japanese medical claim data using propensity score matching
    Shingo Mitsushima, Hiromasa Horiguchi, Kiyosu Taniguchi · 2023 · F1000Research
68. Alpha and Delta variants and vaccination effectiveness against severity in COVID-19 inpatients based on medical claims in Japan
    Shingo Mitsushima, Hiromasa Horiguchi, Kiyosu Taniguchi · 2023 · GHM Open
69. COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis
    Kathrin Marx, Sven Kalbitz, Nils Kellner, Maike Fedders, Christoph Lübbert · 2023 · PubMed Central
70. Biophysical evolution of the receptor-binding domains of SARS-CoVs
    Vaibhav Upadhyay, Sudipta Panja, Alexandra Lucas, Casey Patrick, Krishna M.G. Mallela · 2023 · Biophysical Journal
71. Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data
    Antonio Russo, Pierantonio Grimaldi, Mariantonietta Pisaturo, Lorenzo Onorato, Nicola Coppola · 2024 · Frontiers in Immunology
72. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages
    Jean‐Sélim Driouich, Maxime Cochin, Guillaume Lingas, Léa Lucıanı, Cécile Baronti, Ornéllie Bernadin, Magali Gilles, Paola Mariela Saba Villarroel, Grégory Moureau, Paul-Rémi Petit et al. · 2024 · Biomedicine & Pharmacotherapy
73. Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study
    Martina Patone, Andrew JHL Snelling, Holly Tibble, Carol A. C. Coupland, Aziz Sheikh, Julia Hippisley‐Cox · 2025 · Communications Medicine
74. Fournier's gangrene in a COVID ‐19 patient with multiple comorbidities: Combatting the triple threat
    Emanuela Silva‐Alvarenga, Sameh Hany Emile, Steven D. Wexner · 2022 · Colorectal Disease
75. Potential of outpatient steroid therapy in elderly patients with early COVID-19
    Roberto Luzzati, Marina De Luca, Gianfranco Sanson, Massimo Borelli, Gianni Biolo, Donatella Giacomazzi, Verena Zerbato, Stefano Di Bella · 2022 · Aging Clinical and Experimental Research
76. Therapeutics in the Treatment of COVID-19 for Children and Adolescents
    Soo‐Han Choi, Jae Hong Choi, Ki Wook Yun · 2022 · Pediatric Infection & Vaccine
77. Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis—A case report and literature review
    Melek Yalçın Mutlu, Jule Taubmann, Jochen Wacker, Koray Taşçılar, Filippo Fagni, Maximilian Gerner, Daniel Klett, Georg Andreas Schett, Bernhard Manger, David Simón · 2022 · Frontiers in Medicine
78. COVID-19 in patients with B cell immune deficiency
    Paschalis I. Vergidis, Emily Ruth Levy, Elizabeth H. Ristagno, Vivek Iyer, John Charles O’Horo, Avni Y. Joshi · 2022 · Journal of Immunological Methods
79. AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021–2022
    Jennifer Grant, Justin Chan, Sylvain Lother, Lisa Barrett, Paul Bonnar, Aidan Reid Findlater, Sameer S. Kassim, John C. Lam, Donald Cuong Vinh · 2022 · Journal of the Association of Medical Microbiology and Infectious Disease Canada
80. Identifying stable-against-mutations viral epitopes in SARS-CoV-2
    Ildefonso M. De la Fuente, Iker Malaina, Marı́a Fedetz, M. Chruszcz, Gontzal Grandes, Oleg S. Targoni, Antonio Abel Lozano Pérez, Eyal Shteyer, Ami Ben Yaʼacov, Agustı́n Gómez de la Cámara et al. · 2022 · medRxiv
81. On the concept and ethics of vaccination for the sake of others
    Steven R. Kraaijeveld · 2023
82. Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State
    Tina S. Ipe, Blessing Ugwumba, Horace Jack Spencer, Tuan Le, Terry Ridenour, John Armitage, Stefanie Ryan, Shanna Pearson, Atul Kothari, Naveen Patil et al. · 2022 · Laboratory Medicine
83. Computational redesign of Beta-27 Fab with substantially better predicted binding affinity to the SARS-CoV-2 Omicron variant than human ACE2 receptor
    Wantanee Treewattanawong, Thassanai Sitthiyotha, Surasak Chunsrivirot · 2023 · Scientific Reports
84. Variation in Time Between Testing Positive for COVID-19 and Hospital Admission by Race/Ethnicity and Insurance Status
    Austin Porter, Clare C. Brown, Analiz Rodriguez, Namvar Zohoori, Samantha Wells, Alisha A. Crump, José Romero, John Mick Tilford · 2023 · Journal of Health Care for the Poor and Underserved
85. A chemical-pathological study to evaluate the role of vitamin D, ESR, and RF and the prevalence of rheumatoid arthritis and its correlation with disease activity in the centers of Dhi Qar Governorate
    Adeeb Abdulally Abdulhussien Alazbjee, Zainab Mohammed Farhan · 2024 · International Journal of Case Reports in Orthopaedics
86. Efectividad y seguridad de remdesivir y nirmatrelvir-ritonavir en la COVID-19 leve-moderada en los servicios de urgencia hospitalaria españoles
    C. Rodriguez-Leal, Juan María González del Castillo, Martín Sebastián Ruiz Grinspan, Rosario Susi García, Teresa Pérez · 2025 · Medicina Clínica
87. Effectiveness and safety of remdesivir and nirmatrelvir-ritonavir in mild to moderate COVID-19 in Spanish hospital emergency departments
    C. Rodriguez-Leal, Juan María González del Castillo, Martín Sebastián Ruiz Grinspan, Rosario Susi García, Teresa Pérez · 2025 · Medicina Clínica (English Edition)
88. Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy
    Rinki Deo, Manish Chandra Choudhary, Owen T. Glover, Rachel Bender Ignacio, Julie Boucau, Kara W Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan et al. · 2025 · Open Forum Infectious Diseases
89. Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats
    Ahmad Z. Al Meslamani, Anan S. Jarab, Eman Merghani Ali Mohammed, Abdullah Elrefae · 2026 · Expert Opinion on Biological Therapy
90. Direct-acting antivirals and beyond: emerging approaches to targeting viral RNA and ribonucleoprotein complexes
    Xiaoyan Zuo, Xia Xiao, Xiaojing Dong, Jianwei Wang, Xiaobo Lei · 2026 · Antiviral Research
91. Antiviral Drugs, Antibodies, and Vaccines for COVID-19
    Dana M. Barry, Hideyuki Kanematsu · 2022 · Springer eBooks
92. Inside the Mind of the DMC: A Review of Principles and Issues with Case Studies
    Lizhao Ge, Toshimitsu Hamasaki, Scott R. Evans · 2024 · Therapeutic Innovation & Regulatory Science
93. Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V platform trial
    Toby J L Humphrey, Wendi Qian, Michael Chen-Xu, Francis Dowling, Katrina Gatley, Rakshya Adhikari, Tracey Hensman, Louise Stockley, Abhinav Bassi, Nikita Bathla et al. · 2025 · BMC Infectious Diseases
94. An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
    Isabel H Gonzalez-Bocco, Rayven Frierson, Alyssa Cho, Fabiola A. Reyes, Andres E Franceschi, Chloé Lahoud, Dimitrios G Moshovitis, Katherine Beluch, MANU BALUSU, C. Elizabeth Keleher et al. · 2025 · New Microbes and New Infections
95. Efficacy and safety of Toujie Quwen Granules in patients infected with SARS-CoV-2: A prospective cohort study of 156 cases
    Qihua Xu, Xinyue Zhang, Sanqi Huang, Linghua Li, Feng Li, Wei Liu, Kunzhou Ling, Jialong Guan, Xinghua Tan, Luping Lin · 2026 · Chinese Herbal Medicines
96. Re-infection with SARS-CoV-2 is associated with increased antibody breadth and potency against diverse sarbecovirus strains
    Michelle Lilly, Felicitas Ruiz, William B. Foreman, Vrasha Chohan, Jamie Guenthoer, Delphine Depierreux, Viren A. Baharani, Duncan Ralph, Alex Harteloo, Helen Y. Chu et al. · 2026 · mBio
97. Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
    Yasuhiro Osugi, Hitoshi Iwata, Yasushi Imai, Daiki Kobayashi, Ryutaro Hirashima · 2022 · Cureus
98. In Silico Evaluation for the Inhibitory Action of Curcumin Derivatives on the SARS-CoV-2 Proteins
    Areej Jaradat, Yasmeen Salameh, Hilal Zaid, Siba Shanak · 2022 · Journal of Biosciences and Medicines
99. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting
    Alex Belote, Sharon Reece, Samantha Robinson, Hanna Jensen, Sheena W. CarlLee, Megan Clark, Spencer Parnell, Caroline G. Geels, James Newton · 2022 · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
100. COVID-19 treatments
     Linda Vong, Chaim M. Roifman · 2022 · LymphoSign Journal